Chagas Disease Treatment Market To Worth Over US$ 10.29 Mn with 7.3% CAGR up to 2025

Global Chagas Disease Treatment Market – Insights

Chagas disease is an infectious disease caused by a kinetoplastid protozoan parasite found in the feces of the triatomine bug, Trypanosoma cruzi. Although the infection is rare, its prevalence is competitively higher in Latin America compared to rest of the world. The infectious disease can also be transferred through blood transfusion, organ transplantation, and congenital and oral transmissions.

Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/934

The disease has spread to developed regions such as Europe and North America in the recent past, due to migration of people. For instance, according a study published in National Center for Biotechnology Information (NCBI), in 2015, 4.2% of Latin American living in European countries were chronically affected with Chagas disease. The rare disease has low availability of effective therapies and Benznidazole is the only U.S. FDA approved therapy. Another drug Nifurtimox manufactured by Bayer AG, is in the World Health Organization (WHO)’s list of ‘Essential Medicines’ and is used for the treatment of Chagas disease.

Global Chagas Disease Treatment Market: Drivers

Increasing approval of drugs for the treatment of Chagas disease is expected to boost growth of the global Chagas disease treatment market. For instance, in April 2018, Laboratorio Elea Phoenix SA received approval for benznidazole for the treatment of Chagas disease in children from the Argentinian National Administration for Drugs, Food, and Medical Technologies (ANMAT). Moreover, high prevalence of Chagas disease in Latin America is expected to boost growth of the market. For instance, according to data published by Mundo Sano (nongovernmental foundation in Argentina), in 2017, around 7,300,000 people were exposed to Chagas disease and about 1,600,000 were infected, in Argentina.

Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/934

Various government and private organizations are focused on increasing awareness of Chagas disease, which is also expected to boost growth of the global Chagas disease treatment market. For instance, in April 2018, Médecins Sans Frontières/Doctors without Borders (MSF), an international humanitarian organization, launched a campaign aimed at increasing public awareness about Chagas disease as the disease is still prevalent in Latin American countries and affects about 6 million people, globally. Moreover, in 2007, WHO launched a program to increase treatment rate and eliminate Chagas disease. This WHO program was supported by Bayer HealthCare, which manufactures nifurtimox, used in the treatment of Chagas disease. In 2007, Bayer entered into agreement with WHO to support the program by providing 2.5 million tablets free of charge to WHO, for the treatment of an estimated 30,000 patients over a period of five years (from 2007 to 2011). In 2011, WHO and Bayer extended its agreement. According to the agreement, Bayer is expected to provide 5 million tablets, free of charge, from 2012 to 2017.

The global Chagas disease treatment market was valued at US$ 5.67 Mn in 2016 and is expected to witness a CAGR of 7.3% over the forecast period (2017–2025).

Figure 1. Global Chagas Disease Treatment Market Share (%), By Product Type, 2017 & 2025

Source: Coherent Market Insights Analysis (2017)

Diagnostic Methods

Serological, parasitological, and molecular methods are used for the diagnosis of Chagas disease. Parasitological methods include identification of trypomastigotes in blood by microscopy. A widely used molecular diagnosis method is Polymerase Chain Reaction (PCR). Serological method is mostly used in the detection of Trypanosoma cruzi antibodies in blood donors, diagnosis of infected people and for epidemic studies. Some of the widely used tests in serological method include, Enzyme-linked Immunosorbent Assay (ELISA) and Indirect Immunofluorescence (IIF).

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/chagas-disease-treatment-market-to-surpass-us-1029-mn-threshold-by-2025-502

Global Chagas Disease Treatment Market: Competitive Landscape 

Major players operating in the global Chagas disease treatment market include, Laboratorio Elea Phoenix SA, Maprimed S.A., Nortec Quimica SA, Bayer AG, and Laboratório Farmacêutico de Pernambuco S/A.

Key players in the market are focused on product approval and launch to expand their product portfolio. For instance, in 2016, InBios International, Inc. received 510K clearance from the U.S. Food and Drug Administration (FDA) for its Chagas Detect Plus Rapid Test Kit (CDP).

Table of Content

Global Chagas Disease Treatment Market Research Report
Section 1: Global Chagas Disease Treatment Industry Overview
Section 2: Global Economic Impact on Chagas Disease Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Chagas Disease Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Chagas Disease Treatment Market Forecast

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837